1631 related articles for article (PubMed ID: 24239208)
21. Serum-based microRNA signature predicts relapse and therapeutic outcome of adjuvant chemotherapy in colorectal cancer patients.
Ji D; Qiao M; Yao Y; Li M; Chen H; Dong Q; Jia J; Cui X; Li Z; Xia J; Gu J
EBioMedicine; 2018 Sep; 35():189-197. PubMed ID: 30166271
[TBL] [Abstract][Full Text] [Related]
22. Genome-wide Discovery and Identification of a Novel miRNA Signature for Recurrence Prediction in Stage II and III Colorectal Cancer.
Kandimalla R; Gao F; Matsuyama T; Ishikawa T; Uetake H; Takahashi N; Yamada Y; Becerra C; Kopetz S; Wang X; Goel A
Clin Cancer Res; 2018 Aug; 24(16):3867-3877. PubMed ID: 29514841
[No Abstract] [Full Text] [Related]
23. Clinical significance of microRNA-93 downregulation in human colon cancer.
Xiao ZG; Deng ZS; Zhang YD; Zhang Y; Huang ZC
Eur J Gastroenterol Hepatol; 2013 Mar; 25(3):296-301. PubMed ID: 23354160
[TBL] [Abstract][Full Text] [Related]
24. Prognostic relevance of Src activation in stage II-III colon cancer.
Martínez-Pérez J; Lopez-Calderero I; Saez C; Benavent M; Limon ML; Gonzalez-Exposito R; Soldevilla B; Riesco-Martínez MC; Salamanca J; Carnero A; Garcia-Carbonero R
Hum Pathol; 2017 Sep; 67():119-125. PubMed ID: 28601656
[TBL] [Abstract][Full Text] [Related]
25. Development and validation of a microRNA-based signature (MiROvaR) to predict early relapse or progression of epithelial ovarian cancer: a cohort study.
Bagnoli M; Canevari S; Califano D; Losito S; Maio MD; Raspagliesi F; Carcangiu ML; Toffoli G; Cecchin E; Sorio R; Canzonieri V; Russo D; Scognamiglio G; Chiappetta G; Baldassarre G; Lorusso D; Scambia G; Zannoni GF; Savarese A; Carosi M; Scollo P; Breda E; Murgia V; Perrone F; Pignata S; De Cecco L; Mezzanzanica D;
Lancet Oncol; 2016 Aug; 17(8):1137-1146. PubMed ID: 27402147
[TBL] [Abstract][Full Text] [Related]
26. SOX9 expression predicts relapse of stage II colon cancer patients.
Marcker Espersen ML; Linnemann D; Christensen IJ; Alamili M; Troelsen JT; Høgdall E
Hum Pathol; 2016 Jun; 52():38-46. PubMed ID: 26980019
[TBL] [Abstract][Full Text] [Related]
27. Prognostic value of candidate microRNAs in gastric cancer: A validation study.
Zhang L; Huang Z; Zhang H; Zhu M; Zhu W; Zhou X; Liu P
Cancer Biomark; 2017; 18(3):221-230. PubMed ID: 27983528
[TBL] [Abstract][Full Text] [Related]
28. Prognostic and predictive roles of DNA mismatch repair status in colon cancer patients treated with oxaliplatin-based chemotherapy: a retrospective study.
Qin Q; Zhou AP; Yang L; Xu C; Sun YK; Zhang W; Wang JW; Zhong DS
J Physiol Pharmacol; 2020 Aug; 71(4):. PubMed ID: 33316771
[TBL] [Abstract][Full Text] [Related]
29. An Integrated miRNA-lncRNA Signature Predicts the Survival of Stage II Colon Cancer.
Wang XJ; Zeng B; Lin S; Chen M; Chi P
Ann Clin Lab Sci; 2019 Nov; 49(6):730-739. PubMed ID: 31882423
[TBL] [Abstract][Full Text] [Related]
30. Plasma miRNAs in diagnosis and prognosis of pancreatic cancer: A miRNA expression analysis.
Zhou X; Lu Z; Wang T; Huang Z; Zhu W; Miao Y
Gene; 2018 Oct; 673():181-193. PubMed ID: 29913239
[TBL] [Abstract][Full Text] [Related]
31. Prognostic Value of a Four-miRNA Signature in Patients With Lymph Node Positive Locoregional Esophageal Squamous Cell Carcinoma Undergoing Complete Surgical Resection.
Wen J; Wang G; Xie X; Lin G; Yang H; Luo K; Liu Q; Ling Y; Xie X; Lin P; Chen Y; Zhang H; Rong T; Fu J
Ann Surg; 2021 Mar; 273(3):523-531. PubMed ID: 31058700
[TBL] [Abstract][Full Text] [Related]
32. Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study.
André T; de Gramont A; Vernerey D; Chibaudel B; Bonnetain F; Tijeras-Raballand A; Scriva A; Hickish T; Tabernero J; Van Laethem JL; Banzi M; Maartense E; Shmueli E; Carlsson GU; Scheithauer W; Papamichael D; Möehler M; Landolfi S; Demetter P; Colote S; Tournigand C; Louvet C; Duval A; Fléjou JF; de Gramont A
J Clin Oncol; 2015 Dec; 33(35):4176-87. PubMed ID: 26527776
[TBL] [Abstract][Full Text] [Related]
33. A miRNA-based signature predicts development of disease recurrence in HER2 positive breast cancer after adjuvant trastuzumab-based treatment.
Du F; Yuan P; Zhao ZT; Yang Z; Wang T; Zhao JD; Luo Y; Ma F; Wang JY; Fan Y; Cai RG; Zhang P; Li Q; Song YM; Xu BH
Sci Rep; 2016 Sep; 6():33825. PubMed ID: 27650797
[TBL] [Abstract][Full Text] [Related]
34. A 4-microRNA signature predicts lymph node metastasis and prognosis in breast cancer.
Chen X; Wang YW; Zhu WJ; Li Y; Liu L; Yin G; Gao P
Hum Pathol; 2018 Jun; 76():122-132. PubMed ID: 29555574
[TBL] [Abstract][Full Text] [Related]
35. MicroRNA-192-5p is a predictive biomarker of survival for Stage IIIB colon cancer patients.
Li P; Ou Q; Braciak TA; Chen G; Oduncu FS
Jpn J Clin Oncol; 2018 Jul; 48(7):619-624. PubMed ID: 29529220
[TBL] [Abstract][Full Text] [Related]
36. Tumor microRNA-29a expression and the risk of recurrence in stage II colon cancer.
Weissmann-Brenner A; Kushnir M; Lithwick Yanai G; Aharonov R; Gibori H; Purim O; Kundel Y; Morgenstern S; Halperin M; Niv Y; Brenner B
Int J Oncol; 2012 Jun; 40(6):2097-103. PubMed ID: 22426940
[TBL] [Abstract][Full Text] [Related]
37. A Five-MicroRNA Signature Predicts Survival and Disease Control of Patients with Head and Neck Cancer Negative for HPV Infection.
Hess J; Unger K; Maihoefer C; Schüttrumpf L; Wintergerst L; Heider T; Weber P; Marschner S; Braselmann H; Samaga D; Kuger S; Pflugradt U; Baumeister P; Walch A; Woischke C; Kirchner T; Werner M; Werner K; Baumann M; Budach V; Combs SE; Debus J; Grosu AL; Krause M; Linge A; Rödel C; Stuschke M; Zips D; Zitzelsberger H; Ganswindt U; Henke M; Belka C
Clin Cancer Res; 2019 Mar; 25(5):1505-1516. PubMed ID: 30171046
[TBL] [Abstract][Full Text] [Related]
38. Identification and Construction of Combinatory Cancer Hallmark-Based Gene Signature Sets to Predict Recurrence and Chemotherapy Benefit in Stage II Colorectal Cancer.
Gao S; Tibiche C; Zou J; Zaman N; Trifiro M; O'Connor-McCourt M; Wang E
JAMA Oncol; 2016 Jan; 2(1):37-45. PubMed ID: 26502222
[TBL] [Abstract][Full Text] [Related]
39. A four-miRNA signature identified from genome-wide serum miRNA profiling predicts survival in patients with nasopharyngeal carcinoma.
Liu N; Cui RX; Sun Y; Guo R; Mao YP; Tang LL; Jiang W; Liu X; Cheng YK; He QM; Cho WC; Liu LZ; Li L; Ma J
Int J Cancer; 2014 Mar; 134(6):1359-68. PubMed ID: 23999999
[TBL] [Abstract][Full Text] [Related]
40. Transcriptome profiling reveals an integrated mRNA-lncRNA signature with predictive value of early relapse in colon cancer.
Dai W; Feng Y; Mo S; Xiang W; Li Q; Wang R; Xu Y; Cai G
Carcinogenesis; 2018 Oct; 39(10):1235-1244. PubMed ID: 29982331
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
